MedPath

Efficacy of the medical compound of teneligliptin 20 mg and canagliflozin 100 mg with Free Style Libre

Not Applicable
Recruiting
Conditions
type 2 diabetes mellitus
Registration Number
JPRN-UMIN000029015
Lead Sponsor
TDE Healthcare Corporation TOSAKI Clinic for Diabetes and Endocrinology
Brief Summary

http://diabetes.diabetesjournals.org/content/67/Supplement_1/2304-PUB?utm_source=TrendMD&utm_medium=cpc&utm_campaign=Diabetes_TrendMD_0

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
40
Inclusion Criteria

Not provided

Exclusion Criteria

1. Patients who have renal dysfunction (eGFR is less than 30ml/min/1.73m2) 2. Pregnant women 3. Patients judged by the doctor to be ineligible

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Blood glucose transition (standard deviation and MAGE), and average blood glucose level by a Free Style Libre.
Secondary Outcome Measures
NameTimeMethod
Diabetes Treatment Satisfaction: DTSQ, glycoalbumin, urine albumin creatinine ratio, eGFR, glucagon, bodyweight.
© Copyright 2025. All Rights Reserved by MedPath